Spots Global Cancer Trial Database for homoharringtonine
Every month we try and update this database with for homoharringtonine cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Pharmacokinetic (PK) Study of Homoharringtonine (Omacetaxine Mepesuccinate) Administered Subcutaneously to Patients With Advanced Solid and Hematologic Tumors | NCT00675350 | Hematologic Tum... | Omacetaxine | 18 Years - | Teva Branded Pharmaceutical Products R&D, Inc. | |
| Homoharringtonine (Omacetaxine Mepesuccinate) in Treating Patients With Chronic Myeloid Leukemia (CML) With the T315I BCR-ABL Gene Mutation | NCT00375219 | Chronic Myeloid... | Omacetaxine mep... | 18 Years - | Teva Branded Pharmaceutical Products R&D, Inc. | |
| Efficacy Study of CHG Regimen vs Decitabine to Treat Higher-risk MDS | NCT01417767 | Myelodysplastic... | CHG regimen 5-aza-deoxycyti... | 16 Years - 80 Years | Shanghai 6th People's Hospital | |
| Chemotherapy and Biological Therapy in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia | NCT00003239 | Leukemia | Recombinant Int... Cytarabine Omacetaxine Mep... | 12 Years - | M.D. Anderson Cancer Center | |
| Efficacy Study of CHG Regimen vs Decitabine to Treat Higher-risk MDS | NCT01417767 | Myelodysplastic... | CHG regimen 5-aza-deoxycyti... | 16 Years - 80 Years | Shanghai 6th People's Hospital | |
| A Pivotal Study of HQP1351 in Patients With Chronic Myeloid Leukemia in Chronic Phase | NCT04126681 | Chronic Myeloid... | HQP1351 Hydroxyurea or ... Homoharringtoni... Imatinib, Dasat... | 18 Years - | Ascentage Pharma Group Inc. | |
| A Pivotal Study of HQP1351 in Patients With Chronic Myeloid Leukemia in Chronic Phase | NCT04126681 | Chronic Myeloid... | HQP1351 Hydroxyurea or ... Homoharringtoni... Imatinib, Dasat... | 18 Years - | Ascentage Pharma Group Inc. | |
| Venetoclax Combined With Homoharringtonine and Cytarabine in Induction for AML | NCT05805098 | Acute Myeloid L... | Venetoclax Homoharringtoni... Cytarabine | 18 Years - 60 Years | The First Affiliated Hospital of Soochow University | |
| Homoharringtonine With Oral Gleevec in Chronic, Accelerated and Blast Phase Chronic Myeloid Leukemia (CML) | NCT00114959 | Myeloid Leukemi... Myeloid Leukemi... Blast Phase Myeloid Leukemi... | Homoharringtoni... Imatinib Mesyla... | 16 Years - | Teva Branded Pharmaceutical Products R&D, Inc. | |
| Omacetaxine and Decitabine in Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS) | NCT02141477 | Leukemia | Omacetaxine Decitabine | 70 Years - | M.D. Anderson Cancer Center | |
| Efficacy Study of CHG Regimen vs Decitabine to Treat Higher-risk MDS | NCT01417767 | Myelodysplastic... | CHG regimen 5-aza-deoxycyti... | 16 Years - 80 Years | Shanghai 6th People's Hospital | |
| Homoharringtonine (Omacetaxine Mepesuccinate) in Treating Patients With Chronic Myeloid Leukemia (CML) With the T315I BCR-ABL Gene Mutation | NCT00375219 | Chronic Myeloid... | Omacetaxine mep... | 18 Years - | Teva Branded Pharmaceutical Products R&D, Inc. | |
| Open Label Study of Subcutaneous Homoharringtonine (Omacetaxine Mepesuccinate) in Patients With Advanced CML | NCT00462943 | Chronic Myeloid... | Omacetaxine mep... | 18 Years - | Teva Branded Pharmaceutical Products R&D, Inc. | |
| Pharmacokinetic (PK) Study of Homoharringtonine (Omacetaxine Mepesuccinate) Administered Subcutaneously to Patients With Advanced Solid and Hematologic Tumors | NCT00675350 | Hematologic Tum... | Omacetaxine | 18 Years - | Teva Branded Pharmaceutical Products R&D, Inc. | |
| Chemotherapy and Biological Therapy in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia | NCT00003239 | Leukemia | Recombinant Int... Cytarabine Omacetaxine Mep... | 12 Years - | M.D. Anderson Cancer Center | |
| Open Label Study of Subcutaneous Homoharringtonine (Omacetaxine Mepesuccinate) in Patients With Advanced CML | NCT00462943 | Chronic Myeloid... | Omacetaxine mep... | 18 Years - | Teva Branded Pharmaceutical Products R&D, Inc. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
